Report for: Impact of rapid molecular testing on diagnosis, treatment and management of community-acquired pneumonia in Norway: a pragmatic randomised controlled trial (CAPNOR)

Title	Impact of rapid molecular testing on diagnosis, treatment and management of community-acquired pneumonia in Norway: a pragmatic randomised controlled trial (CAPNOR)
Published in	Trials, August 2022
DOI	10.1186/s13063-022-06467-7
Pubmed ID	35915452
Authors	Sondre Serigstad, Christian Ritz, Daniel Faurholt-Jepsen, Dagfinn Markussen, Marit H. Ebbesen, Øyvind Kommedal, Rune O. Bjørneklett, Lars Heggelund, Tristan W. Clark, Cornelis H. van Werkhoven, Siri T. Knoop, Elling Ulvestad, Harleen M. S. Grewal

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.

Country	Count	As %
Peru	1	33%
Unknown	2	67%

Type	Count	As %
Members of the public	3	100%

Mendeley readers

The data shown below were compiled from readership statistics for 51 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Country	Count	As %
Unknown	51	100%

Readers by professional status	Count	As %
Unspecified	8	16%
Researcher	6	12%
Student > Doctoral Student	2	4%
Other	2	4%
Student > Bachelor	2	4%
Other	7	14%
Unknown	24	47%

Readers by discipline	Count	As %
Unspecified	8	16%
Medicine and Dentistry	7	14%
Agricultural and Biological Sciences	3	6%
Pharmacology, Toxicology and Pharmaceutical Science	2	4%
Nursing and Health Professions	2	4%
Other	2	4%
Unknown	27	53%

Impact of rapid molecular testing on diagnosis, treatment and management of community-acquired pneumonia in Norway: a pragmatic randomised controlled trial (CAPNOR)